Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 11/20 | 0.38 |
| ▸ | MMP13 | P45452 | 7/20 | 0.37 |
| ▸ | MMP3 | P08254 | 4/20 | 0.35 |
| ▸ | MMP2 | P08253 | 4/20 | 0.35 |
| ▸ | MMP8 | P22894 | 2/20 | 0.35 |
| ▸ | MMP12 | P39900 | 2/20 | 0.35 |
| ▸ | CETP | P11597 | 4/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7606682 | 0.91 | MMP1 (0.35) | MMP1MMP13MMP3MMP2MMP8 | |
| SCHEMBL7607525 | 0.82 | MMP1 (0.37) | MMP1MMP13MMP3MMP2MMP8 | |
| SCHEMBL7607399 | 0.79 | PTPN1 (0.47) | MMP1MMP13CETP | |
| SCHEMBL7603936 | 0.78 | FDPS (0.43) | MMP1MMP13 | |
| SCHEMBL7607456 | 0.76 | CETP (0.32) | MMP1CETP | |
| SCHEMBL7609232 | 0.76 | CETP (0.36) | MMP1CETP | |
| SCHEMBL6037795 | 0.75 | CETP (0.34) | MMP1MMP13CETP | |
| SCHEMBL7604385 | 0.74 | ACP3 (0.41) | MMP1MMP13CETP | |
| SCHEMBL7609842 | 0.74 | PTPN1 (0.43) | MMP1CETP | |
| SCHEMBL7606830 | 0.73 | RAB9A (0.35) | MMP1MMP13MMP3MMP2MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2002515040-A | — | — | 2002-05-21 | — | — | JP | claimed |
| JP-2002514160-A | — | — | 2002-05-14 | — | — | JP | claimed |
| JP-2002514184-A | — | — | 2002-05-14 | — | — | JP | claimed |
| EP-1005348-A1 | NAALADASE COMPOSITIONS AND METHODS FOR TREATING GLUTAMATE ABNORMALITY AND EFFECTING NEURONAL ACTIVITY IN ANIMALS | GUILFORD PHARMACEUTICALS INC. (US) | 2000-06-07 | — | — | EP | claimed |
| EP-0954295-A1 | METHODS OF CANCER TREATMENT USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1999-11-10 | — | — | EP | claimed |
| EP-0936914-A4 | — | — | 1999-08-25 | — | — | EP | claimed |
| EP-0936914-A1 | HYDROXY-PHOSPHINYL DERIVATIVES USEFUL AS NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1999-08-25 | — | — | EP | claimed |
| WO-1998013046-A1 | NAALADASE COMPOSITIONS AND METHODS FOR TREATING GLUTAMATE ABNORMALITY AND EFFECTING NEURONAL ACTIVITY IN ANIMALS | GUILFORD PHARMACEUTICALS INC. (US) | 1998-04-02 | — | — | WO | claimed |
| WO-1997048400-A1 | HYDROXY-PHOSPHINYL DERIVATIVES USEFUL AS NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1997-12-24 | — | — | WO | claimed |
| WO-1997048409-A1 | METHODS OF CANCER TREATMENT USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1997-12-24 | — | — | WO | claimed |
| EP-1044206-A1 | PRODRUGS OF NAALADASE INHIBITORS | Guildford Pharmaceuticals Inc. (US) | 2000-10-18 | — | — | EP | disclosed |
| EP-1005348-A1 | NAALADASE COMPOSITIONS AND METHODS FOR TREATING GLUTAMATE ABNORMALITY AND EFFECTING NEURONAL ACTIVITY IN ANIMALS | GUILFORD PHARMACEUTICALS INC. (US) | 2000-06-07 | — | — | EP | disclosed |
| EP-0954295-A1 | METHODS OF CANCER TREATMENT USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1999-11-10 | — | — | EP | disclosed |
| EP-0949922-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING COMPULSIVE DISORDERS USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1999-10-20 | — | — | EP | disclosed |
| EP-0936914-A4 | — | — | 1999-08-25 | — | — | EP | disclosed |
| WO-1999033849-A1 | PRODRUGS OF NAALADASE INHIBITORS | GUILDFORD PHARMACEUTICALS INC. (US) | 1999-07-08 | — | — | WO | disclosed |
| WO-1998013044-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING COMPULSIVE DISORDERS USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1998-04-02 | — | — | WO | disclosed |
| WO-1998013046-A1 | NAALADASE COMPOSITIONS AND METHODS FOR TREATING GLUTAMATE ABNORMALITY AND EFFECTING NEURONAL ACTIVITY IN ANIMALS | GUILFORD PHARMACEUTICALS INC. (US) | 1998-04-02 | — | — | WO | disclosed |
| WO-1997048400-A1 | HYDROXY-PHOSPHINYL DERIVATIVES USEFUL AS NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1997-12-24 | — | — | WO | disclosed |
| WO-1997048409-A1 | METHODS OF CANCER TREATMENT USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1997-12-24 | — | — | WO | disclosed |